Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 9/28/2006 First Published: 8/1/1998


1.		Phase III Randomized Study of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Versus Doxorubicin, Vinblastine, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone (Stanford V) With or Without Radiotherapy in Patients With Locally Extensive or Advanced Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 and over				NCI				ECOG-2496 CAN-NCIC-HD7, CALGB-59905, SWOG-E2496, E2496, NCT00003389, HD7

Last Modified: 9/1/2001


2.		Phase II Study of a Short-Term Stanford V Regimen Comprising Mechlorethamine, Doxorubicin, Vinblastine, Prednisone, Vincristine, Bleomycin, and Etoposide Followed by Modified Involved-Field Radiotherapy in Patients With Favorable, Limited-Stage Hodgkin's Disease (Summary Last Modified 09/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 to 60				NCI				SUMC-G4 NCI-H96-0805, NCT00002714

Last Modified: 5/12/2004


3.		Phase II Pilot Study of the Stanford V Regimen in Patients With Stage IIB, IIIA, IIIB, or IV Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 60				NCI				SUMC-G2/G3 NCI-H96-0806, NCT00002715

Last Modified: 11/19/2007 First Published: 4/1/1998


4.		Phase II Study of Chemotherapy in Patients with Hodgkin's Disease and HIV Infection: Stanford V Regimen for Low Risk Patients, EBVP Regimen for High Risk Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				ITA-GICAT-POS5 EU-97022, NCT00003262

Last Modified: 7/1/1994


5.		Phase II Pilot Study of Short-Term Combination Chemotherapy with the Stanford V Regimen (NM/DOX/VBL/PRED/VCR/BLEO/VP-16), with Consolidative Radiotherapy as Appropriate, in Unfavorable Hodgkin's Disease (Summary Last Modified 07/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				16 to 60				NCI				E-1492 EST-PF-491, E1492

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute